Mutations in ADNP were recently identified as a frequent cause of syndromic autism, characterized by deficits in social communication and interaction and restricted, repetitive behavioral patterns. Based on its functional domains, ADNP is a presumed transcription factor. The gene interacts closely with the SWI/SNF complex by direct and experimentally verified binding of its Cterminus to three of its core components. A detailed and systematic clinical assessment of the symptoms observed in our patients allows a detailed comparison with the symptoms observed in other SWI/SNF disorders. While the mutational mechanism of the first 10 patients identified suggested a gain of function mechanism, an 11 th patient reported here is predicted haploinsufficient.
INTRODUCTION
Autism is a neurodevelopmental disorder characterized by limitations in social interaction and communication in combination with stereotypic, repetitive behavior and restricted interest [APA 2013 ]. The symptoms usually emerge in early childhood, before the age of three. The prevalence of the disorder appears to be on the rise over the last decades, with as many as 1 in 68 individuals affected according to the most recent estimates [Surveillance 2014 ]. Consistent among all prevalence estimates, more boys than girls are affected. All population studies indicate a significant contribution of genetic components underlying the disorder. While the heritability -the proportion of phenotypic variation explained by genetic factors -was once estimated to be as high as 90% in the first reported twin studies [Folstein and Rutter 1977; Steffenburg and others 1989] , there is now a consensus that these initial studies may have overestimated the genetic contribution of the disorder. The largest population based study so far reports a heritability of 50% with an increased risk of recurrence of about 10-fold for a first degree relative and of about 2-fold for cousins [Sandin and others 2014] .
While the genetic causes of non-syndromic autism remain elusive, searches for a genetic cause have been successful to some extent in syndromic forms of autism. Syndromic autism is defined as autism in combination with additional clinical features. Co-morbidities often observed include intellectual disability, epilepsy and psychiatric disorders. Frequent monogenic causes of syndromic autism include the fragile X syndrome and Rett syndrome [Amir and others 1999; Rooms and Kooy 2011] . Specific genomic disorders-submicroscopic chromosomal deletions or duplications at fixed positions in the genome -presenting with autism, include the duplication of the PraderWilli/Angelman region at 15q11-13 and recurrent copy number variants (CNV) at 16p11.2 [Sanders and others 2011] . A microscopically visible chromosomal abnormality associated with autism is an additional supernumerary isodicentric chromosome 15 [Mendelsohn and Schaefer 2008] . Apart from recurrent genomic disorders, an excess of non-recurrent de novo CNVs as compared to healthy siblings and control subjects is also evident in patients with ASD [Pinto and others 2010] .
Most recently, whole exome -consisting of all protein coding regions in the genomesequencing (WES) has been applied to identify the genes involved in autism. This approach was inspired by the successful introduction of WES to identify genetic causes of neurodevelopmental disorders . After a proof of principle study comparing the exomes of a pilot cohort of 10 ID patients with those of the parents, likely causative mutations were identified in six cases [Vissers and others 2010] . Subsequent studies using the same so called trio approach in larger cohorts of up to 250 patients showed a diagnostic yield in the range of up to 50% [de Ligt and others 2012; Rauch and others 2012; Yang and others 2013] . In autism, it was discovered that de novo potentially deleterious (e.g., amino acid changing) SNPs were significantly more prevalent in patients than in unaffected relatives or controls. Based on the trio and quartet approach, consisting of patient, parents and unaffected sibling, the most frequently mutated genes identified so far include CDH8, SCN2A, DYRK1A and CTNNB1 [Krumm and others 2014; O'Roak and others 2012a] .
Many genes implicated in autism were previously identified as causative for ID, epilepsy, schizophrenia or bipolar disorder, suggesting an overlap in the underlying etiology of neurodevelopmental disorders.
Collectively, the genetic abnormalities identified in autism to date explain maximally 15% of cases [Carter and Scherer 2013; Mendelsohn and Schaefer 2008] . While no single gene is mutated in more than 1% of patients, autism genes functionally converge to commonly affected cellular pathways and protein-protein interaction networks [Krumm and others 2014; O'Roak and others 2012b; Pinto and others 2014] . The most commonly affected networks are the developmental wnt signaling pathway, the pathway involving synaptic function and the chromatin remodeling pathway.
The identification of ADNP mutations in autistic patients
In an attempt to identify novel genes responsible for autism, a first de novo p.Lys408Valfs*31 mutation in the activity-dependent neuroprotective protein (ADNP) gene was identified in a large cohort of autistic patients [O'Roak and others 2012b] . As sequencing of the 209 families in this cohort did not reveal a second mutation in ADNP nor hardly in any other candidate gene, a large scale resequencing study of the most promising candidates, including ADNP, was initiated using the molecular inversion probe (MIP) sequencing technology [O'Roak and others 2012a] . In this study of 2446 probands, an additional p.Tyr719* de novo ADNP mutation was identified. However, a single p.Q361* mutation in a patient of the NHLBI GO Exome Sequencing Project (ESP) cohort, consisting of patients with non-neurological disorders affecting heart, lung and blood was present, and it was concluded that statistical evidence was not sufficient to prove causality of the mutations [ESP] .
Confusingly, a p.Gly1094Profs*5 mutation, inherited from an unaffected parent, was reported in this same large scale targeted resequencing study. While this finding seemed to argue against causality at first sight, this mutation is located close to the C-terminus of the encoded protein, beyond the last known functional domain. Typically variations that close to the end of a protein are unlikely to affect protein function.
In a trial of optimizing the diagnostic workflow for the introduction of WES in a diagnostic setting, we discovered another ADNP mutation in a small cohort of ID/autism patients [Helsmoortel and others Submitted] . Targeted screening of a cohort of 148 autistic patients revealed yet another mutation. By combing the data from WES and targeted resequencing studies initiated in multiple centers, we identified a total of 10 patients with mutations in ADNP, including the cases described above [Helsmoortel and others 2014] . We calculated that the frequency of truncating de novo mutations in ADNP is significantly higher (p: 0.001852, odds ratio 13.24668, one-sided Fisher's exact test) in patients compared to the ESP cohort and additional controls from the Simons Siblings. In addition to the case-control analysis, we calculated a locus specific enrichment for truncating variation using a probabilistic model as described [O'Roak and others 2012a] . The probability of detecting 8 or more de novo truncating events in ADNP within our cohort by chance was estimated to be p = 2.65e-18 (binomial test) under a de novo rate of 1.2 non-synonymous coding variants per individual. To further delineate the clinical characteristics of this novel disorder, an online portal was set up to collect phenotypic information of additional patients in a collaborative effort (Figure 1 ).
Today, one additional patient with a de novo c.118C>T (p.Q40*) mutation was already submitted to the system.
The ADNP gene
The ADNP gene was first identified in murine P19 carcinoma cells as a vasoactive intestinal peptide (VIP) responsive gene showing increased expression after VIP treatment [Bassan and others 1999; Pinhasov and others 2003] . VIP is a neuroprotective peptide that is active during embryonic development, especially during the time of neuronal tube closure, and protects damaged nerve cells from cell death by inducing glia-derived, survival promoting substances [Said 1996 ]. The human orthologue, ADNP, spans about 40 kb of genomic DNA and consists of 5 exons and 4 introns with alternative splicing of an untranslated second intron [Zamostiano and others 2001] . Human and murine mRNA are 90% identical and the region is highly conserved between vertebrates. The encoded protein contains 9 zinc fingers and a homeobox domain with a strong homology to that found in hox genes, suggesting a firm role in embryonic development ( Figure 2 ). Bioinformatic analysis also identified PxVxL as a potential heterochromatin protein 1 α (HP1 α) binding motif, together with an ARKS motif in the homeobox domain [Mosch and others 2011] . Indeed, HP1 α is found in co-immunoprecipitates from P19 nuclear protein extracts with ADNP antibodies and vice versa. Additional proteins in the precipitates with ADNP antibodies were BRG1, BAF250A and BAF170, all members of the mating-type switching/sucrose nonfermenting (SWI/SNF) remodeling complex. Despite the presence of a bipartite nuclear localization signal (NLS), the protein is predominantly, but not exclusively, cytoplasmatic in neuronal cells, though in non-neural cells it is mostly located in the nucleus [Gennet and others 2008; Mandel and others 2008] . The protein also contains signals involved in cellular secretion and uptake and ADNP has been found in the extracellular space of VIP stimulated astrocytes [Furman and others 2004] . Finally, ADNP exhibits a strong neuroprotective function that can be attributed in its entirety to an octapeptide Asn-Ala-ProVal-Ser-Ile-Pro-Ala or NAPVSPIQ domain called NAP [Bassan and others 1999; Magen and Gozes 2014] . The mechanism of action is believed to involve P53, a key regulator of cellular apoptosis, as silencing of ADNP results in an increase of p53 [Zamostiano and others 2001] . Subsequently, it was shown that addition of NAP to PC12 cells subjected to oxidative stress protected the cells against elevated p53 levels, normally caused by this treatment [Gozes and others 2004] . ADNP2 is a sister protein to ADNP which is 33% identical at the protein level, shares the zinc finger and homeobox domains, but lacks the NAP motif [Zamostiano et al., 2001] . Expression levels of ADNP and ADNP2 appear to be correlated [Dresner and others 2011; Helsmoortel and others 2014] .
ADNP Knockout Mouse Model
A knockout mouse model has been generated by targeted replacement of the protein coding exons III-V with a neomycin cassette [Pinhasov and others 2003] . Homozygous mice are not viable and die prenatally at E8.5-9 due to a failure of cranial neural tube closure. Heterozygous mice develop normally, be it with a slight developmental delays. A detailed differential expression analysis of E9 full knockout, heterozygous and control mice in parallel with the same analysis in P19 cells showed a significant upregulation of genes involved in lipid transport, lytic vacuoles and coagulation. Interestingly, treatment with NAP or its derivative isoNAP was able to, at least partially, ameliorate the abnormalities in the behavioral tests.
CLINICAL PRESENTATION
All patients suffered from autism, co-morbid in each case with mild to severe intellectual disability. Dysmorphic features as described in the first cohort of 10 patients included a prominent forehead, high hairline, eversion or notch of the eyelid, broad nasal bridge and thin upper lip [Helsmoortel and others 2014] . In the meantime an 11 th patient has been identified. His phenotype shares many of the characteristics of the first 10 patients (Tables 1 and 2 ). 
Mutational mechanism
The first reported patients all had stop mutations in the fifth and last exon of ADNP. Consistent with predicted escape from nonsense mediated decay for mRNA mutations in the last exon, ADNP mRNA levels were not downregulated in the four available cell lines of patients with stop mutations [Helsmoortel and others 2014; Kervestin and Jacobson 2012] . Unexpectedly, instead of downregulation, overexpression of the ADNP transcripts was observed in these cell lines. Because 3 of the mutations clustered within basepairs of each other, we were able to discriminate between expression of the mutant and wildtype mRNA. Despite the presence of only one functional ADNP copy, this analysis showed unaltered mRNA levels of the wild-type transcript and the excess level of mRNA in these patients corresponds to the amount of mutated mRNA. It would be interesting to see whether the mutated RNA is translated into protein, but Western blots have so far not been reported for these patients. Recently, the expression of the ADNP gene was reported to be auto-regulated by a negative feedback loop mechanism [Oz and others 2012] . Hence, a plausible explanation for the observed overexpression in the cell lines of the patients is the inability of the mutant protein to bind to its own promoter region, resulting in a homeostatic correction by up regulation of transcription.
These observations are compatible with a dominant negative mutational mechanism. A dominant negative model is also in line with a discordance in over-or underexpression in our patients versus the results in mice/P19 cells for several genes, but p53 and ADNP2 [Helsmoortel and others 2014; Vulih-Shultzman and others 2007] . However, since the initial report on 10 patients, an 11 th patient has been identified with a stop mutation in the fourth exon, which is unlikely to escape nonsense mediated decay. Since the clinical presentation of this patient is not different from that of patients with a mutation in exon 5, it challenges the dominant negative hypothesis as the only mutational mechanism. It would be interesting to investigate whether the homeostatic correction of ADNP mRNA levels observed in the initial patients with mutations in exon 5, escaping nonsense mediated decay, is present in this patient, where mRNA degradation is predicted. 
Therapeutic potential of NAP
The octapeptide NAP has femtomolar activity and is able to restore some of the anomalies caused by haploinsufficiency of the entire ADNP protein [Bassan and others 1999; Zamostiano and others 2001] . In cellular models, it is able to protect the cells from chemical, electrical or stress induced damage [reviewed in Gozes and others 2005] . The presumed mode of action is NAPs ability to bind to tubulin, facilitating microtubule assembly and increasing cellular survival. Davunetide, the drug name for NAP, is a candidate for the treatment of multiple selected neurological disorders [Gozes 2011 ]. Intranasal and intravenous formulations of the drug exist and both have been shown to cross the blood-brain barrier [Gozes and others 2000a; Leker and others 2002] . The drug has been in Phase II and even in Phase III clinical trials and appears to be well tolerated without significant side-effects [Magen and Gozes 2014] . As stated above, specific cognitive abnormalities were also ameliorated by NAP in an Adnp heterozygous knockout mouse model. While these observations may raise hope for treatment in patients with ADNP mutations, it has to be noted that the mouse model has not been evaluated for autistic traits so far. Consequently, it is not known whether davunetide is able to interfere with the autistic traits. A second point of interest is that, generally speaking, drug testing in a mouse model needs independent confirmation because of the intrinsic variance associated with this type of experiments and because environmental conditions might interfere with the test result [Crabbe and others 1999; Wahlsten and others 2003] .
EPILOGUE
The data presented show that mutations in the ADNP gene cause syndromic autism. These The clinical heterogeneity of these cohorts diminishes the chances that identical mutations are found in two or more patients with a strong clinical resemblance. If this hypothesis is correct, the phenotypic spectrum of many existing, clinically well delineated rare disorders is likely to expand in the post-exomic era [Yu et al., 2013] .
It remains to be seen whether specific ADNP mutations may be associated with nonsyndromic autism. The phenotypes of the patients reported here, range from severe autism, comorbid with ID to less severely affected patients. It is very well possible that the phenotype in larger cohorts of patients with truncating or less damaging ADNP mutations will expand into a much milder range. Seemingly, support of this hypothesis comes from the presence of a likely pathogenic ADNP mutation in the ESP cohort. However, care should be taken in treating ESP as a healthy control cohort with regard to neurological disorders. This is illustrated by multiple likely pathogenic variants in several other genes involved in SWI/SNF related syndromes (Table 3) , we identified in the ESP database by in silico analysis [Kircher and others 2014; Tsurusaki and others 2012] . Unfortunately, detailed phenotypic information is not available on the individuals included in these control databases. The detailed molecular and phenotypical characterization of larger patient cohorts extending in all age groups is mandatory for a better understanding of the role of ADNP mutations in human disease.
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Legends to figures:
Figure 1: http://adnpgene.com forms a portal of a collaborative research project to further characterize the phenotype and future development of patients with ADNP mutations. 
